|
|
Article: Nitric oxide accelerates regression in head and neck cancer.
- Article from:
- Biotech Week
- Article date:
- October 20, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 OCT 20 - (NewsRx.com & NewsRx.net) -- Nitric oxide accelerates interleukin-13 cytotoxin-mediated regression in head and neck cancer animal model.
"Receptors for interleukin-13 (IL-13R) are overexpressed on several types of solid cancers including gliobastoma, renal cell carcinoma, AIDS Kaposi's sarcoma, and head and neck cancer. Recombinant fusion proteins IL-13 cytotoxin (IL13-PE38QQR or IL13-PE38) have been developed to directly target IL-13R-expressing cancer cells. Although it has been found that IL-13 cytotoxin has a direct potent antitumor activity in vivo in nude mice models of human cancers, the involvement of indirect antitumor effecter molecules ...
Related newspaper, magazine, and journal articles:
|
|
Article: Reports outline head and neck cancer ...
Cancer Weekly;
December 23, 2008 ;
700+ words
... ... colleagues, University of Piemonte Orientale (see also Head and Neck Cancer). The researchers concluded: PET/CT fusion images could ... Keywords: Italy, Novara, Drug Development, Head and Neck Cancer, Head and Neck Carcinoma, Oncology, Pharmaceuticals, Surgery ...
|
|